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Erns glycoprotein, along with E1 and E2, is one of the three envelope glycoproteins of classical swine fever virus (CSFV). E
rns is a heavily
glycosylated protein involved in several functions, including virus attachment and entry to target cells, production of neutralizing antibodies, and
virulence. The role of added glycans to CSFV strain Brescia Erns on virus virulence was assessed in swine. A panel of virus mutants was constructed
and used to investigate whether the removal of each of seven putative glycosylation sites in the Erns glycoprotein would affect viral virulence in swine.
Only N269A/Q substitution rendered attenuated viruses (N1v/N1Qv) that, unlike BICv and other mutants, produced a transient infection in swine
characterized by mild symptoms and decreased virus shedding. Notably, N1v efficiently protected swine from challenge with virulent BICv at 3 and
21 days post-infection suggesting that glycosylation of Erns could be modified for development of CSF live-attenuated vaccines.
Published by Elsevier Inc.Keywords: Virulence; Pathogenesis; Attenuation; Protection; Glycoproteins; Glycosylation; Classical swine fever virusIntroduction
Classical swine fever (CSF) is a highly contagious disease of
swine caused by CSFV, an enveloped, positive sense, single-
stranded RNA Pestivirus in the Flaviviridae family (Becher
et al., 2003). The 12.5 kb CSFV genome contains a single open
reading frame that encodes a 3898-amino acid polyprotein, that
after co- and post-translational processing by cellular and viral
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doi:10.1016/j.virol.2007.08.028anchored to the envelope at their carboxyl termini and Erns
loosely associates with the viral envelope (Thiel et al., 1991)
Modifications introduced into these glycoproteins appear to
have an important effect on CSFV virulence (Meyers et al.,
1999; Risatti et al., 2005a,b, 2006, 2007a,b; Van Gennip et al.,
2004). Even though glycosylation of Erns, E1, or E2 proteins may
play a significant role in the lifecycle of CSFV, the function of
added oligosaccharides is not well known. We have recently
reported that glycosylation of E2 plays a role in virulence of
CSFV strain Brescia (Risatti et al., 2007b). A single mutation,
N805A, in one of the six N-linked glycosylation sites in
E2 rendered a completely attenuated virus.
Erns from Pestiviruses possess several biological activities.
Erns lacks a typical membrane anchor and is secreted from
infected cells but is associated with mature virions (Rumenapf
et al., 1993), it contains ribonuclease activity (Schneider et al.,
1993), its C-terminal domain controls translocation across
eukaryotic cell membranes (Langedijk, 2002), and has a role
in the inhibition of double-stranded RNA-induced cell responses
(Iqbal et al., 2004). An important feature is that Erns is heavily
Fig. 1. (A) Schematic representation of glycosylation mutants of Classical Swine Fever Virus Erns protein, generated by site-directed mutagenesis of a cDNA full-
length clone pBIC. Wild-type Erns glycoprotein is shown at the top. Y: putative glycosylation sites. Mutants were named with an N (N-linked glycosylation) followed
by a number that represents the relative position of putative glycosylation sites within Erns amino acid sequence (N1, N2, N3, N4, N5, N6 and N7) starting from the
amino terminus. (B) In vitro growth characteristics of Erns individual glycosylation mutants and parental BICv. Primary swine macrophage cell cultures were infected
(MOI=0.01) with each of the mutants or BICv and virus yield titrated at times post-infection in SK6 cells. Data represent means and standard deviations from two
independent experiments. Sensitivity of virus detection:≥ log10 1.8 TCID50/ml. (C) Plaque formation of Erns glycosylation mutants and BICv. SK6 monolayers were
infected, overlaid with 0.5% agarose and incubated at 37 °C for 3 days. Plates were fixed with 50% (vol/vol) ethanol-acetone and stained by immunohistochemistry
with mAb WH303 (Edwards et al., 1991).
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Fig. 2. Erns glycoprotein analysis was done by Western immunoblot of reducing
(A) or non-reducing (B) 12% SDS-PAGEs. SK6 monolayers were infected
(MOI=1) with each of the mutants or parental BICv and harvested 48 h post-
infection. CSFV Erns was detected with mAb 16/15 (kindly provided by Prof.
J-H Thiel, Institut für Virologie, Frankfurter, Germany).
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counting for up to half of the apparent molecular weight
(Branza-Nichita et al., 2004). In this study, we used oligonucle-
otide site-directed mutagenesis of the highly virulent CSFV
strain Brescia Erns gene to construct a panel of seven individual
glycosylation mutants (at positions N269, N274, N278, N332,
N362, N410 and N425 of the CSFV polyprotein). These mutants
were applied to investigate whether the removal of each of these
glycosylation sites in the Erns glycoprotein could affect viral
infectivity and virulence in swine. We found that one of the
seven single mutations introduced in Erns, N269 substituted byA
or Q, renders an attenuated virus (N1v/N1Qv) with decreased
virus replication and shedding in infected swine.Table 1
Swine survival and fever response following infection with CSFV Erns glycosylatio







BICv 0/4 8.5 (1) 4.5 (0.5
N1v 5/5ba – 5.6 (0.5
N2v 0/2 6.5 (0.7) 5 (0.4
N3v 0/2 7.5 (2.1) 4 (0)
N4v 0/2 9 (2.8) 4 (0)
N5v 0/2 7.5 (0.7) 4 (0)
N6v 0/2 8.5 (2.1) 4 (0)
N7v 0/2 11 (0) 4 (0)
N1Qv 3/3 – 6 (0)
a The original experiment performed with 2 animals were repeated with 3 more in
b Only 2 out of 5 animals showed fever.Results
Replication of glycosylation mutants in vitro
Infectious RNAwas in vitro transcribed from full-length ICs
of the CSFV Brescia strain or a set of glycosylation mutants and
used to transfect SK6 cells. Mutants referred to as N1, N2, N3,
N4, N5, N6, and N7 represent each of seven putative
glycosylation sites starting from the N terminus of Erns
(Fig. 1A). Nucleotide sequences of the rescued virus genomes
were identical to parental DNA plasmids, confirming that only
mutations at predicted glycosylation sites were reflected in
rescued viruses.
In vitro growth characteristics of mutant viruses N1v, N2v,
N3v, N4v, N5v, N6v, andN7vwere evaluated relative to parental
BICv in a multistep growth curve performed in swine
macrophage cell cultures (Fig. 1B). All single glycosylation
site mutants, except N1v, exhibited growth characteristics
indistinguishable from BICv. N1v exhibited a lower rate of
growth and a 5- to 10-fold decrease in the final virus yield
(Fig. 1B). Additionally, N1v exhibited a reduction in plaque size
relative to BICv and other mutants in SK6 cell cultures (Fig. 1C).
Analysis of relative electrophoretic mobility of Erns in virus
mutants
Erns glycosylation status of BICv and mutant viruses was
analyzed in lysates of SK6-infected cells by Western immuno-
blots using monoclonal antibody (mAb) 16/15. Assuming that
differences in Erns mobility among mutants and parental viruses
are likely due to the number of carbohydrate moieties attached
to the protein, we observed that Erns from single mutants N1v,
N3v, N4v, N6v and N7v migrated further than Erns from
mutants N2v, N5v or parental BICv (Fig. 2A). The data
suggested that N1, N3, N4, N6 and N7 sites, but not N2 and N5
sites in BICv Erns, are targeted for the addition of glycans in
swine SK6 cells. Furthermore, the lack of glycosylation at N1,
N3, N4, N6 and N7 sites does not appear to alter the formation
of Erns homodimers as revealed by Western blot analysis of
SK6 cell lysates run on non-reducing SDS–PAGEs (Fig. 2B).
Bands with apparent molecular masses of 48 and 80 kDa,n mutants and parental BICv
ays to onset
D)




) 3.5 (0.5) 106.4 (0.9)
)b 3.2 (0.5) 104.6 (1.1)
) 3 (0) 105.2 (0.3)
4 (1.4) 105.8 (0.9)
5.5 (2.1) 106.4 (0.5)
3.5 (0.7) 106.4 (0.6)
4.5 (2.1) 106.5 (0.1)
7 (0) 106.9 (0.9)
2 (0) 105.1 (1.3)
dividuals. Presented results represent data from both experiments.
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as described elsewhere (Weiland et al., 1999; Branza-Nichita
et al., 2004), were observed in all infected lysates (Fig. 2B). An
expected shift in electrophoretic mobility of these bands was
observed in lysates from SK6 cells infected with N1v, N3v,
N4v, N6, and N7v. BICv-infected SK6 cell extracts treated with
(PNGase F) showed a 27- to 29-kDa band, the expected
unglycosylated molecular mass of Erns (Fig. 2A) as described
before (Branza-Nichita et al., 2004).
Mutant N1v lacks determinants necessary for CSFV virulence
in swine
Virulence of Erns glycosylation mutants was analyzed in
swine. An initial screening was established in 16 pigs (10- to 12-Fig. 3. Hematological data (panels on the left) and virus titers (panels on the right) of
parental BICv. Peripheral white blood cell (WBC), lymphocytes (Lymph) and platel
standard deviations from at least two animals per inoculated virus. Virus titers in nasa
and standard deviations from at least two animals per inoculated virus. Sensitivity oweek-old, 40-lb commercial breed) that were randomly allocated
into 8 groups of 2 animals each, and were intranasally (IN)
inoculated with 105 TCID50 of one of each single glycosylation
mutant, or virulent BICv. After inoculation, swine were
monitored daily for clinical disease and changes in body
temperature (Risatti et al., 2005a). Blood, nasal swabs and tonsil
scrapings were collected at times post-infection, processed,
titrated, and analyzed as described by Risatti et al. (2007b).
While BICv exhibited a characteristic virulent phenotype
with animals dying by days 8–9 post-infection, animals
inoculated with N1v survived the infection presenting a short
period of mild fever and transient diarrhea. Conversely, animals
infected with N2v, N3v, N4v, N5v, N6v and N7v showed CSF
with clinical presentation and severity similar to that observed
in animals inoculated with BICv (Table 1). Mutations wereblood samples from animals infected with CSFV Erns glycosylation mutants and
et (PLT) counts are expressed as counts/μl of blood. Data represent means and
l swabs, tonsil scrapings and blood are expressed as the mean log10 TCID50/ml
f virus detection: ≥ log10 1.8 TCID50/ml.
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isolated from infected animals.
Total white blood cell, lymphocyte and platelet counts
dropped by 4 to 6 days post-infection (DPI) in animals
inoculated with N2v, N3v, N4v, N5v, N6v, N7v and BICv and
kept declining until death. In opposition, a transient decrease of
cell counts was observed in animals inoculated with N1v
(Fig. 3).
Furthermore, N1v was attenuated and showed a restricted in
vivo replication capability. Viremia in N1v inoculated animals
was transient and significantly reduced by 103 to 104 from that
observed in pigs infected with BICv and other glycosylation
mutants (Fig. 3). A similar pattern was observed for virus titers
from tonsil samples, and with no virus titers detected in nasal
samples obtained from N1v-infected animals (with a sensitivity
of ≥ log10 1.8 TCID50/ml) (Fig. 3). Interestingly, all the other
mutants retained the same capability of causing severe disease
in swine as parental BICv, showing that in vivo Erns functions
are retained and not influenced by the lack of glycans at
positions N274, N278, N332, N362, N410 and N425.
To determine if N1v attenuation is, beside the lack of
glycosylation in residue N269, due to an intrinsic characteristic
of the N to A substitution, a N269Q virus (N1Qv), harboring a
more conserved residue substitution was constructed. N1Qv
showed in vitro growth characteristics similar to N1v (data not
shown). Animals inoculated via the intranasal route with 105
TCID50 of N1Qv developed, as the N1v-infected animals did,
a transient disease characterized by mild fever, depression and
diarrhea. Hematological and virological values of these
animals also resembled those of the N1v-infected animals
(Fig. 3).
N1v mutant protects pigs against lethal CSFV challenge
Since N1v showed a restricted in vivo growth as observed
with live-attenuated CSFV vaccine CSICv (Risatti et al.,
2005b), the ability of N1v to induce protection against virulent
BICv was assessed in early and late vaccination–exposure
experiments. Three groups of pigs (n=4) received intranasal
inoculation of 103 TCID50 N1v or were mock-inoculated. AtTable 2
Detection of virus in nasal swabs, tonsil scrapings, and blood samples obtained from
Challenge group Sample Days post-challenge
Ca 4
3 DPI Nasal 0/4b 0/4
Tonsil 0/4 1/4 (1.97)c
Blood 0/4 1/4 (1.97)
21 DPI Nasal 0/4 0/4
Tonsil 0/4 0/4
Blood 0/4 0/4
Mock-vaccinated Nasal 0/3 0/3
Tonsil 0/3 0/3
Blood 0/3 3/3 (2.6)
a C, day of challenge.
b Number of animals positive for virus isolation over total number of challenged
c Numbers in parentheses indicate average virus titers expressed as log10 TCID50/
d All mock-vaccinated animals died or were euthanized in extremis by 12 DPC.3 DPI or 21 DPI, animals were challenged with BICv along with
mock-vaccinated animals. Mock-vaccinated animals developed
CSF and died or were euthanized in extremis by 12 days post-
challenge (DPC) (Table 2). Conversely, N1v induced complete
protection by 3 and 21 DPI. All pigs survived infection and
remained clinically normal through the observation period.
Mock-inoculated pigs showed high virus titers in the blood and
oronasal cavity starting 4 DPC (Table 2). Virus was detected in
blood and tonsils in one animal challenged at 3 DPI, by 4 DPC;
while no virus was detected in samples obtained from animals
challenged at 21 DPI. Additionally, no significant hematolog-
ical changes were recorded in any of the challenged animals
(data not shown).
Discussion
CSFV strain Brescia Erns glycoprotein contains 7 putative
N-linked glycosylation sites (http://www.cbs.dtu.dk/services/)
(Moormann et al., 1990) (Fig. 1A). Comparative sequence
analysis of Erns glycoproteins showed that these sites (N269,
N274, N278, N332, N362, N410 and N425 of CSFV
polyprotein) are highly conserved among CSFVs. Five of
them, at positions N269, N278, N332, N362, and N410 are also
highly conserved among Pestiviruses (BVDV type I and II, and
BDV) (data not shown), implying a significant role for these
sites in the viral cycle of all Pestiviruses. In this study, we used
oligonucleotide site-directed mutagenesis of the highly virulent
CSFV strain Brescia Erns gene to construct a panel of glyco-
sylation mutants. These mutants were investigated to determine
whether the removal of each of these glycosylation sites in the
Erns glycoprotein could affect viral infectivity and virulence in
swine. Results demonstrated that one of these sites (N269) has a
major role in virulence and protection and, interestingly, not all
of the sites seem to be essential for in vitro or in vivo infectivity.
Electrophoretic mobility analysis of the Erns glycoprotein
shows that amino acid residues N269 (N1v), N278 (N3v), N332
(N4v), N410 (N6v) and N425 (N7v) are used for carbohydrate
addition (Fig. 2). In vitro growth characteristics and virus pro-
geny yields of these mutants assessed in primary swine ma-
crophage cultures, a CSFV natural target cell, were comparableN1v vaccinated animals after challenge of with virulent BICv at 3 and 21 DPI
6 8 12 14 21
0/4 0/4 0/4 0/4 0/4
0/4 0/4 0/4 0/4 0/4
0/4 0/4 0/4 0/4 0/4
0/4 0/4 0/4 0/4 0/4
0/4 0/4 0/4 0/4 0/4
0/4 0/4 0/4 0/4 0/4
3/3 (4.1) 3/3 (6.4) 3/3 (5.2)d
3/3 (4.2) 3/3 (5.4) 3/3 (4.7)
3/3 (6.6) 3/3 (7.5) 3/3 (7.4)
animals.
ml for 4 animals.
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demonstrated delayed growth kinetics (Fig. 1B). Suggestive of a
role for CSFV Erns glycosylation patterns in virus attachment,
entry, and/or exit from infected cells was the small plaque
phenotype exhibited by single mutant N1v in which a subs-
tantial plaque size reduction relative to parental BICv was
observed in infected SK-6 cells (Fig. 1C). Similarly, loss of one
specific N-linked glycosylation site (G4) from the hemagglu-
tinin–neuraminidase protein (HN) of Newcastle Disease Virus
(NDV) yields plaques in cultured cells of considerably smaller
size (Panda et al., 2004), while three other single mutants (G1,
G2, and G3) produced plaques comparable to the size of the
parental virus. Interestingly, G4 virus was considerably atten-
uated in chickens (Panda et al., 2004; McGinnes and Morrison,
1995). In the case of CSFV, we have observed that other BICv-
derived viruses containing recombinant E2 protein (Risatti et
al., 2005a, 2007a,b) have shown reduced plaque size as well.
Like N1v described here, those recombinant viruses were also
attenuated in swine. Cleavage and glycosylation patterns of the
hemagglutinin and neuraminidase genes of H5 avian influenza
viruses have also been shown to affect pathogenicity in
chickens (Deshpande et al., 1987; Horimoto and Kawaoka,
1994; Hulse et al., 2004). As described for NDV, the
mechanisms by which these patterns affect virus virulence are
unknown.
N1v within Erns rendered attenuated viruses with restricted
in vivo replication ability (Table 1 and Fig. 3). Unlike the acute
fatal disease induced by BICv, infections caused by N1v
mutants were sub-clinical in swine and characterized by de-
creased viral replication and reduced virus shedding. Interest-
ingly, mutants N2v, N3v, N4v, N5v, N6v and N7v retained the
same capability of causing severe disease in swine as parental
BICv, showing that in vivo Erns functions are retained and not
influenced by the lack of glycans at positions, N274, N278,
N332, N362, N410 and N260, suggesting a specific function for
glycan residues added at position N269. The mutation in N1v
seems to be stable, since the N269A substitution was observed
in viruses isolated after four passages in SK6 cells as well as in
viruses isolated from infected pigs at 6 DPI, where the virus is
expected to undergo an unknown number of replication/passage
events (data not shown).
Erns has previously been reported to play a role in CSFV
virulence. Mutations at residues H297 and H346 abrogate Erns
RNase activity, resulting in attenuation of parental CSFV strain
Alfort/Tübingen (Meyers et al., 1999). Although we have not
evaluated the RNase activity of N1v/N1Qv Erns, their atten-
uating mutation, N269A, is not involved in the Erns RNase
motif. Importantly, it has been shown that RNase activity in
Pestiviruses is not affected by N-glycosylation inhibitors
(Branza-Nichita et al., 2004). Therefore, if CSFV attenuation
caused by mutations at residues H297 and H346 is mediated by
loss in RNase activity, attenuation in N1v/N1Qv should be
mediated by different mechanisms.
There is no information on the role of glycosylation in
Pestivirus virulence. We have recently reported that amino
acid substitution N805Awithin the CSFV polyprotein E2 gene
led to complete attenuation of the virulent strain Brescia(Risatti et al., 2007a). This result, along with the data
presented here, demonstrates a significant role of glycosyla-
tion in CSFV virulence in vivo. In BVDV it has been
observed that inhibitors of N-glycosylation do not affect Erns
native conformation as judged by retention of RNase activity
of the protein, or dimerization; however secretion of Erns into
the media is severely impaired, suggesting that trafficking of
the protein within the secretory pathway is affected (Branza-
Nichita et al., 2004). Impairment of viral secretion, mediated
by α-glucosidase inhibitors, results in reduction of infectivity
of newly BVDV released viral particles (Durantel et al.,
2001). With the exception of N1v, we have observed that
removal of individual N-glycosylation sites in the CSFV Erns
protein do not affect virus replication in vitro or in vivo.
These Erns mutants retained the same phenotypic features of
parental BICv when tested in primary swine cultured cells or
in swine.
In summary, we determined the utilization of five out of
seven putative N-glycosylation sites in the CSFV strain Brescia
Erns protein. Individual N-linked glycosylation sites are not
essential for in vitro or in vivo virus infectivity, and one site,
N269, was shown to be involved in attenuation of BICv. The
effective protective immunity elicited by N1v suggests that




Swine kidney cells (SK6), free of BVDV, were cultured in
Dulbecco's minimal essential media (DMEM) (Gibco, Grand
Island, NY) with 10% fetal calf serum (FCS) (Atlas Biologicals,
Fort Collins, CO) (Risatti et al., 2005a). CSFV Brescia strain
was propagated in SK6 cells and used for the construction of an
infectious cDNA clone (Risatti et al., 2005a). Growth kinetics
was assessed on primary swine macrophage cell cultures pre-
pared as described by Zsak et al. (1996). Titration of CSFV from
clinical samples was performed using SK6 cells in 96-well
plates (Costar, Cambridge, MA). Viral infectivity was detected,
after 4 days in culture, by an immunoperoxidase assay using the
CSFV monoclonal antibody WH303 (Edwards et al., 1991) and
the Vectastain ABC kit (Vector Laboratories, Burlingame, CA).
Titers were calculated using the method of Reed and Muench
(1938) and expressed as TCID50/ml. As performed, test
sensitivity was≥1.8 TCID50/ml. Plaque assays were performed
using SK6 cells in 6-well plates (Costar). SK6 monolayers were
infected, washed, overlaid with 0.5% agarose and incubated at
37 °C for 3 days. Plates were fixed with 50% (vol./vol.)
ethanol–acetone and stained by immunohistochemistry with
mAb WH303 (Risatti et al., 2005a).
Construction of CSFV Erns glycosylation mutants
Each of the Erns N-linked glycosylation sites, predicted by
analysis tools from the Center for Biological Sequence Analysis
(http://www.cbs.dtu.dk/services/), were mutated in a full-length
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(Risatti et al., 2005a). N to A (N to Q for N1Qv) substitutions
were introduced by site-directed mutagenesis using the
QuickChange XL Site-Directed Mutagenesis kit (Stratagene,
Cedar Creek, TX), performed per manufacturer's instructions
and using the following primers (only 5′→3′ forward primer
sequences are shown; italics represent base substitutions,
mutated codons are underlined); N1v: TACCAACCTGTTG-
CAGCCGAA GCTATAACTCAATGGAACCTGAGT; N1Qv:
TACCAACCTGTTGCAGCCGAACA GATAACTCAATG-
GAACCTGAGT; N2v : GCCGAAAATATAACT-
CAATGGGCCC T GAGTGACAAGCGTACCAAT; N3v:
ACTCAATGGAACCTGAGTGACGCCGGTA CCAATGG-
TATCCAGCAC; N4v: ATGGATGCCAGCGAGGGGA-
CA GCCTATACGT GCTGTAAGTTACAG; N5v :
GACCCCTGGATACAGTTGATGGCTAGAACCCAAG
CAAACTTGGCA; N6v: ACTGGCTGCAAGAAAGG-
GAAAGCTTTTTCTTTTGCGG GTACAGTT; N7v: ATA-
GAGGGCCCATGTAATTTCGCCGTTTCTGTTGAGGATA
TCTTA. Mutants were referred to as N1, N2, N3, N4, N5, N6
and N7, representing each of the seven putative glycosylation
sites starting from the N terminus of Erns (N269, N274, N278,
N332, N362, N410 and N425 of the CSFV polyprotein, res-
pectively) (Fig. 1A).
In vitro rescue of CSFV Brescia and glycosylation mutants
Full-length genomic clones were linearized with SrfI and
in vitro transcribed using the T7 Megascript system (Ambion,
Austin, TX). RNA was precipitated with LiCl and transfected
into SK6 cells by electroporation at 500 V, 720Ω, 100 W with a
BTX 630 electroporator (BTX, San Diego, CA) as described by
Risatti et al. (2005a). Cells were seeded in 6-well plates and
incubated for 4 days at 37 °C and 5% CO2. Virus was detected
by immunoperoxidase staining as described above, and stocks
of rescued viruses were stored at −70 °C.
Full-length clones and in vitro rescued viruses were com-
pletely sequenced with CSFV specific primers by the
dideoxynucleotide chain-termination method (Sanger et al.,
1977). Viruses recovered from infected animals were sequenced
in themutated area. Sequencing reactions were preparedwith the
Dye Terminator Cycle Sequencing Kit (Applied Biosystems,
Foster City, CA). Reaction products were sequenced on a
PRISM 3730xl automated DNA sequencer (Applied Biosys-
tems). Sequence data were assembled with the Phrap software
program (http://www.phrap.org). The final DNA consensus
sequence represented an average 5-fold redundancy at each base
position. Sequence comparisons were conducted using BioEdit
software (http://www.mbio.ncsu.edu/BioEdit/bioedit.html).
Western blot analysis
Glycosylation status of the Erns glycoprotein of BICv and
mutant viruses was analyzed in lysates of SK6-infected cells by
Western immunoblots. CSFV Erns was detected using mono-
clonal antibody (mAb) 16/15 (kindly provided by Prof. J.-H.
Thiel, Institut für Virologie, Justus Liebig Universität Giessen,Frankfurter, Germany). Cell extract preparation, Western
immunoblots, and Peptide N-glycosidase F (PNGase F)
digestions were performed as described by Risatti et al. (2007a).
Animal infections
Each of the Erns glycosylation mutants was screened for its
virulence phenotype in swine relative to virulent Brescia virus.
Swine used in all animal studies were 10- to 12-week-old, 40-lb
commercial breed pigs inoculated intranasally with 105 TCID50
of either mutant or wild-type virus. For screening, 16 pigs were
randomly allocated into 8 groups of 2 animals each, and pigs in
each group were inoculated with one of the Erns glycosylation
mutants or BICv. Clinical signs (anorexia, depression, fever,
purple skin discoloration, staggering gait, diarrhea and cough)
and changes in body temperature were recorded daily through-
out the experiment as previously described (Risatti et al.,
2007a).
For protection studies, 12 pigs were randomly allocated into
3 groups of 4 animals each. Pigs in groups 1 and 2 were
inoculated with N1v, and pigs in group 3 were mock-infected.
At 3 DPI (group 1) or 28 DPI (group 2), animals were
challenged with BICv along with animals in group 3. Clinical
signs and body temperature were recorded daily throughout the
experiment as described above. Blood, serum, nasal swabs and
tonsil scrapings were collected at times post-challenge, with
blood obtained from the anterior vena cava in EDTA-containing
tubes (Vacutainer) for total and differential white blood cell
counts. Total and differential white blood cell and platelet
counts were obtained using a Beckman Coulter ACT (Beckman,
Coulter, CA).
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